Very little in the numbers to be thrilled about. Increasing revenues but increased costs ate them up. Net income is less than the prior year. But since they are making a profit and have decent revenue, it IS difficult to understand why this is a 78 cent stock. It seems that there are political forces in play that don't favor them.
I'm kind of surprised at the increase in income taxes paid. They had previously said that they had received a special dispensation on taxes for 2011 which would lower their taxes.
Hopefully, the claim that they expect approval for a new drug by mid year will bear some fruit. They still don't make it clear what the big holdup is on the generic form of Crestor. Other countries are manufacturing it.
Interesting about the mystery coronary heart disease drug that is now in Phase III development. Does anyone know what it is and what it does?
I thought the company was going to stumble based on teh price, but they had net income of $18 million. That should conservatively put the market cap around $90 million. But market cap is only around $35 million. We could easily see a 2.5X rise based on these numbers. PPS of $2.20/sh to 2.60/sh is coming.